SYRE · Spyre Therapeutics, Inc.
$88.50
-0.83 (-0.93%)
At close · Sep 1
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$7.97B
Shares
88.17M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-08-11 | 2,448 | $105.33 | $257,848 |
| 2026-07-22 | 961 | $102.70 | $98,695 |
| 2026-07-21 | 4,468 | $97.33 | $434,870 |
| 2026-07-20 | 821 | $100.23 | $82,289 |
| 2026-07-17 | 2,395 | $94.12 | $225,417 |
| 2026-07-16 | 56 | $102.07 | $5,716 |
| 2026-07-07 | 6,039 | $88.74 | $535,901 |
| 2026-06-30 | 6,600 | $90.16 | $595,056 |
| 2026-06-29 | 4,555 | $87.89 | $400,339 |
| 2026-06-26 | 5,392 | $88.67 | $478,109 |
| 2026-06-22 | 207,327 | $88.34 | $18,315,267 |
| 2026-06-18 | 2,977 | $87.49 | $260,458 |
| 2026-06-17 | 74 | $83.41 | $6,172 |
| 2026-06-16 | 3 | $83.58 | $251 |
| 2026-06-15 | 514 | $80.79 | $41,526 |
| 2026-06-11 | 1,753 | $75.08 | $131,615 |
| 2026-06-05 | 6 | $78.48 | $471 |
| 2026-06-03 | 73 | $69.16 | $5,049 |
Showing 1–18 of 18 settlements
Key facts
CIK
1636282
CUSIP
00773J202
13F (30d)
240 filings
237 filers
Visit website
Investor relations